Switching between anti-calcitonin gene-related peptide monoclonal antibodies: A comparison of monthly and quarterly dosing

• Published in: Journal of the neurological sciences Vol. 453; p. 120811
• Main Authors: Ihara, Keiko, Ohtani, Seiya, Watanabe, Narumi, Takahashi, Nobuyuki, Miyazaki, Naoki, Takemura, Ryo, Hori, Satoko, Nakahara, Jin, Takizawa, Tsubasa
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.10.2023
• Subjects: Antibodies, Monoclonal - adverse effects; Calcitonin Gene-Related Peptide; CGRP; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fremanezumab; Galcanezumab; Hospitals, University; Humans; Injection Site Reaction; Migraine; Migraine Disorders; Neurology; Real-world; Retrospective Studies; Switch; Treatment Outcome; RR; Fremanezumab; FH; MMD; Migraine; CI; Real-world; MOH; MHD; EM; Galcanezumab; CM; NRS; Switch; AMD; CGRP; CGRPmAb; BMI; anti-calcitonin gene-related peptide monoclonal antibody; monthly migraine days; monthly headache days; numerical rating scale; International Classification of Headache Disorders, 3rd edition; chronic migraine; ICHD-3; responder rate; body mass index; monthly acute medication days; calcitonin gene-related peptide; medication overuse headache; episodic migraine; family history; confidence interval
• ISSN: 0022-510X; 1878-5883; 1878-5883
• DOI: 10.1016/j.jns.2023.120811

Anti-calcitonin gene-related peptide monoclonal antibodies (CGRPmAbs) have dramatically changed preventive treatment options for patients with migraine. Although there is emerging real-world evidence on the use of CGRPmAbs globally, the change in efficacy and safety after switching between CGRPmAbs owing to patients' frequency of hospital visits preference remains unknown. We conducted a single-centre, retrospective, real-world study of patients with migraine who first received galcanezumab for 3 or 4 months and then switched to fremanezumab at Keio University Hospital. We investigated changes in monthly migraine days (MMD), responder rate, and adverse effects such as injection site reactions. MMD increased only by 0.7 (95% CI, −4.1–5.5; p = 0.748) after 4 months of treatment with fremanezumab (6.1, 95% CI, 2.3–9.9) compared to before switching (5.4, 95% CI, 2.2–8.6). Furthermore, switching from galcanezumab to fremanezumab produced only minor adverse events, such as injection site reactions. After switching from galcanezumab to fremanezumab out of the desire to visit the hospital less often, the reduction in MMD compared to baseline was sustained, and no serious adverse effects were observed.